





CLAIMS:

1. A compound having the following structure:




wherein each R is independently at each occurrence hydrogen or comprises a poly(ethylene glycol) (PEG) group or an ethylene glycol group, a linker group, and an end group.

10 2. The compound of claim 1, wherein the linker group has the following structure:



wherein X is a spacer group.




15 3. The compound of claim 1, wherein the end group has the following structure:




wherein L is O or -CH2- and Z is OH, O, or H, wherein O is chelated to M, R' is

independently at each occurrence chosen from hydrogen, halogens, aliphatic groups, aryl groups, alkoxide groups, amine groups, carboxylate groups, carboxylic acids, ether groups, alcohol groups, alkyne groups, and combinations thereof, and x is 1, 2, 3, or 4.


- 5 4. The compound of claim 3, wherein the end group has the following structure:




5. The compound of claim 3, wherein the end group has the following structure:




(Formula IVa),




(Formula IVb),




(Formula IVc),



(Formula IVd),




(Formula IVe), or




(Formula IVf).

5


6. The compound of claim 1, wherein the compound has the following structure:




(Formula Va),



(Formula Vb),






(Formula Vc), R''-O-CH2-CH2-O-R'' (Formula Vd), or




(Formula Ve),

wherein R'' is independently at each occurrence H or






- 5 wherein M is a divalent cation, R' is independently at each occurrence chosen from halogens, aliphatic groups, aryl groups, alkoxide groups, amine groups, carboxylate groups, carboxylic acids, ether groups, alcohol groups, alkyne groups, and combinations thereof, A is one or more counter anions, x is 1, 2, 3, or 4, and n is 1–500.

- 10 7. The compound of claim 6, wherein the compound has the following structure:



wherein R''' is independently at each occurrence H or



and n is 1–500.

5

8. A composition comprising a compound of claim 1 and one or more pharmaceutically acceptable carriers.

9. The composition of claim 8, further comprising an anti-PD1 antibody, an anti-CTLA-4
10 antibody, an anti-LAG3 antibody, an anti-TIM3 antibody, or a combination thereof.

10. The composition of claim 9, wherein the anti-PD1 antibody is chosen from nivolumab, pembrolizumab, durvalumab, camrelizumab, cemiplimab, sintilimab, toripalimab, and combinations thereof.

15

11. A liposome composition, wherein the liposomes have incorporated therein a compound
claim 1.
12. The liposome composition of claim 11, wherein the liposome has a monolayer or bilayer
5 and the monolayer or bilayer comprise phosphatidylcholine ("PC") and/or
phosphatidylglycerol ("PG") and, optionally, cholesterol.
13. A method of treating an individual in need of treatment for cancer, comprising
administering to the individual one or more compounds of claim 1 or one or more
10 compositions comprising a compound of claim 1.
14. The method of claim 13, wherein the cancer is a solid tumor, leukemia, lymphoma, or a
combination thereof.
- 15 15. The method of claim 14, wherein the solid tumor is associated with melanoma.
16. The method of claim 13, wherein the composition is a liposomal composition.
17. The method of claim 13, wherein the individual is a human.
20
18. The method of claim 13, wherein the individual is a non-human mammal.